These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 3439205

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Whole blood viscosity in patients with acral arterial occlusive diseases and their modification by rheologically active drugs].
    Runge E, Thiele P.
    Z Gesamte Inn Med; 1987 Mar 01; 42(5):137-41. PubMed ID: 3590891
    [Abstract] [Full Text] [Related]

  • 4. The influence of I.V. application of pentoxifylline on the viscoelasticity of blood in patients with peripheral vascular disorders.
    Chmiel H, Anadere I, Heimburg P.
    Ric Clin Lab; 1981 Mar 01; 11 Suppl 1():189-96. PubMed ID: 7188108
    [Abstract] [Full Text] [Related]

  • 5. [Hyper- or isovolemic hemodilution in patients with stage II peripheral arterial occlusive disease].
    Kiesewetter H, Jung F, Blume J, Spitzer S, Birk A.
    Acta Med Austriaca; 1991 Mar 01; 18 Suppl 1():23-7. PubMed ID: 1719729
    [Abstract] [Full Text] [Related]

  • 6. [Iso- and hypervolemic hemodilution with hydroxyethyl starch (HES 200/.05 10%) in patients with II b peripheral arterial occlusive disease].
    Kiesewetter H, Blume J, Jung F, Spitzer S, Gerhards M, Waldhausen P, Wenzel E.
    Wien Med Wochenschr; 1989 Sep 15; 139(17):396-401. PubMed ID: 2480029
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Effects of pentoxifylline on blood viscosity and peripheral hemodynamics in patients with peripheral occlusive arteriopathies].
    Guerrini M, Pecchi S, Rossi C, Cappelli R, Pieragalli D, Acciavatti A.
    Ric Clin Lab; 1981 Sep 15; 11 Suppl 1():265-79. PubMed ID: 7188114
    [No Abstract] [Full Text] [Related]

  • 9. [Therapeutic efficacy of pentoxifylline in peripheral artery diseases: its clinical value].
    Benignetti G, Fabbri F, Benvenuti C.
    Clin Ter; 1983 Feb 28; 104(4):297-304. PubMed ID: 6861465
    [No Abstract] [Full Text] [Related]

  • 10. [Therapeutic consequences of hemorheologic research].
    Ernst E.
    Wien Med Wochenschr; 1989 Dec 31; 139(24):569-80. PubMed ID: 2696217
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Hypervolemic hemodilution with medium molecular-weight hydroxyethyl starch: effect of duration of administration on viscoelasticity of blood in IIa and IIb peripheral arterial occlusive disease].
    Költringer P, Langsteger W, Lind P, Klima G, Pierer G, Reisecker F, Eber O.
    Acta Med Austriaca; 1991 Dec 31; 18 Suppl 1():45-7. PubMed ID: 1719731
    [Abstract] [Full Text] [Related]

  • 16. [Induced hemodilution as a new concept in the therapy of peripheral circulatory disorders].
    Rieger H.
    Internist (Berl); 1982 Jul 31; 23(7):375-82. PubMed ID: 7049999
    [No Abstract] [Full Text] [Related]

  • 17. [Hemorheologic therapy in peripheral arterial occlusive disease].
    Kiesewetter H, Jung F.
    Fortschr Med; 1984 Oct 04; 102(37):921-4. PubMed ID: 6500451
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hypervolumetric hemodilution with HES 100/0.5 10% in patients with peripheral arterial occlusive disease (Fontaine, stage II): an open clinical and pharmacological phase IV study.
    Koscielny J, Latza R, Pruss A, Kiesewetter H, Jung F, Meier C, Schimetta W.
    Clin Hemorheol Microcirc; 2000 Oct 04; 22(1):53-65. PubMed ID: 10711822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.